Benutzer: Gast  Login
Titel:

and Amplifications Determine Response to HER2 Inhibition in -Amplified Esophagogastric Cancer.

Dokumenttyp:
Journal Article
Autor(en):
Sanchez-Vega, Francisco; Hechtman, Jaclyn F; Castel, Pau; Ku, Geoffrey Y; Tuvy, Yaelle; Won, Helen; Fong, Christopher J; Bouvier, Nancy; Nanjangud, Gouri J; Soong, Joanne; Vakiani, Efsevia; Schattner, Mark; Kelsen, David P; Lefkowitz, Robert A; Brown, Karen; Lacouture, Mario E; Capanu, Marinela; Mattar, Marissa; Qeriqi, Besnik; Cecchi, Fabiola; Tian, Yuan; Hembrough, Todd; Nagy, Rebecca J; Lanman, Richard B; Larson, Steven M; Pandit-Taskar, Neeta; Schöder, Heiko; Iacobuzio-Donahue, Christine A;...     »
Abstract:
The anti-HER2 antibody trastuzumab is standard care for advanced esophagogastric (EG) cancer with (HER2) amplification or overexpression, but intrinsic and acquired resistance are common. We conducted a phase II study of afatinib, an irreversible pan-HER kinase inhibitor, in trastuzumab-resistant EG cancer. We analyzed pretreatment tumor biopsies and, in select cases, performed comprehensive characterization of postmortem metastatic specimens following acquisition of drug resistance. Afatinib r...     »
Zeitschriftentitel:
Cancer Discov
Jahr:
2019
Band / Volume:
9
Heft / Issue:
2
Seitenangaben Beitrag:
199-209
Sprache:
eng
Volltext / DOI:
doi:10.1158/2159-8290.CD-18-0598
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/30463996
Print-ISSN:
2159-8274
TUM Einrichtung:
Klinik und Poliklinik für Nuklearmedizin
 BibTeX